The Yisheng development pipeline is supported in part by an established commercial and manufacturing organization. Yisheng markets the YivykaTM anticancer therapy in Cambodia for the treatment of advanced solid tumors. The Yisheng YSJATM Rabies Vaccine is the first aluminum-free lyophilized rabies vaccine in China, with more rapid induction of protective antibodies and improved tolerability as compared to previously available vaccines. The YSJATM Rabies Vaccine has been available commercially in China and has been used to treat over 15 million patients since 2003.
Product information is available here: Pharmaceutical Product Quality and Safety Statement 药品质量安全承诺书.